The role of GLP-1 receptor agonists in managing type 2 diabetes
Noura Nachawi, Pratibha PR Rao, Vinni Makin
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus, have cardioprotective and renoprotective effects, and do not cause weight gain or significant hypoglycemia. In fact, they have been found to be effective for weight loss in patients with obesity with and without diabetes. They are now the preferred drugs to add to the regimen when oral metformin by itself is not enough to meet the patient's hemoglobin A1c goal.
Topics & Concepts
MedicineMetforminGlycemicHypoglycemiaType 2 diabetesWeight lossDiabetes mellitusGlucagon-like peptide 1 receptorType 2 Diabetes MellitusInternal medicineGlucagon-like peptide-1EndocrinologyAgonistRegimenPharmacologyObesityReceptorDiabetes Treatment and ManagementDiet and metabolism studiesPharmacology and Obesity Treatment